U.S. Pharmaceutical Analytical Testing Outsourcing Market Size, Share & Trends Analysis Report By Services, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies, Contract Research Organizations), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
U.S. Pharmaceutical Analytical Testing Outsourcing Market Growth & Trends
The U.S. pharmaceutical analytical testing outsourcing market size is expected treach USD 5.09 billion by 2030, according ta new report by Grand View Research, Inc. The market is anticipated texpand at a CAGR of 8.5% from 2025 t2030. Technological advancements in the healthcare industry and an increase in end-users are the key factors driving the growth of the U.S. market.
Analytical testing services outsourcing allows companies thandle more complex or repetitive tasks while alsassisting companies in concentrating on their core competencies. Enabling medical organizations tavoid developing specialized facilities and hiring staff, results in cost savings. The identification and measurement of ingredients in drugs or therapeutic solutions are included in pharmaceutical analytical testing. The market is anticipated texpand during the assessment period as a result of rising R&D investments and rising drug demand.
The outsourcing of pharmaceutical analytical testing has been significantly impacted by the COVID-19 pandemic. Due tvarious pharmaceutical companies' internal lab testing capacities being reduced or shut down, the pharmaceutical analytical services-an important component of the healthcare infrastructure-were initially disrupted. The workers initially faced several difficulties, including reduced lab capacity because of concerns about spreading the virus, IT issues, and difficulties sending samples for testing. However, various strategies, including rotating shifts, reducing manpower, and working from home, have been adopted by companies tmitigate or prevent these difficulties.
Various companies supported the government's efforts tstop the COVID-19 pandemic by producing various cutting-edge tests and solutions. These businesses were able treduce the effects of COVID-19 on their operations. For example, 40 million COVID-19 tests were successfully manufactured by Eurofins laboratories. Additionally, new test kits are being created for various variants. When WHO classified it as a variant of concern, they released an omicron test kit the same day.
U.S. Pharmaceutical Analytical Testing Outsourcing Market Report Highlights
U.S. Pharmaceutical Analytical Testing Outsourcing Market Growth & Trends
The U.S. pharmaceutical analytical testing outsourcing market size is expected treach USD 5.09 billion by 2030, according ta new report by Grand View Research, Inc. The market is anticipated texpand at a CAGR of 8.5% from 2025 t2030. Technological advancements in the healthcare industry and an increase in end-users are the key factors driving the growth of the U.S. market.
Analytical testing services outsourcing allows companies thandle more complex or repetitive tasks while alsassisting companies in concentrating on their core competencies. Enabling medical organizations tavoid developing specialized facilities and hiring staff, results in cost savings. The identification and measurement of ingredients in drugs or therapeutic solutions are included in pharmaceutical analytical testing. The market is anticipated texpand during the assessment period as a result of rising R&D investments and rising drug demand.
The outsourcing of pharmaceutical analytical testing has been significantly impacted by the COVID-19 pandemic. Due tvarious pharmaceutical companies' internal lab testing capacities being reduced or shut down, the pharmaceutical analytical services-an important component of the healthcare infrastructure-were initially disrupted. The workers initially faced several difficulties, including reduced lab capacity because of concerns about spreading the virus, IT issues, and difficulties sending samples for testing. However, various strategies, including rotating shifts, reducing manpower, and working from home, have been adopted by companies tmitigate or prevent these difficulties.
Various companies supported the government's efforts tstop the COVID-19 pandemic by producing various cutting-edge tests and solutions. These businesses were able treduce the effects of COVID-19 on their operations. For example, 40 million COVID-19 tests were successfully manufactured by Eurofins laboratories. Additionally, new test kits are being created for various variants. When WHO classified it as a variant of concern, they released an omicron test kit the same day.
U.S. Pharmaceutical Analytical Testing Outsourcing Market Report Highlights
- The bioanalytical testing segment dominated the market with a revenue share of 52.2% in 2024 due tplayers in the biopharmaceutical industry spending money on R&D and a growing preference for outsourcing analytical testing.
- By method development and validation segment, the extractable and leachable services held 23.55% segment share in 2024.
- The pharmaceutical companies segment accounted for the largest share of 45.61% in 2024. Changing regulations for in vitrand in vivtests, sophisticated technologies, and creative methods treduce test complexity are some of the factors that are causing more pharmaceutical analytical testing services tbe outsourced.
- West Pharmaceutical Services, Inc., SGS SA, Eurofins Scientific, Pace Analytical Services Llc, and Intertek Group Plc are some of the major key players contributing tthe growth of the market.
- Based on end-user, biopharmaceutical companies are anticipated tregister the fastest growth over the forecast period due tan increase in the number of clinical trial registrations and market entrants.
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Services
1.2.2. End Use
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing innovation in testing services
3.2.1.2. Growing regulation, safety & quality requirements
3.2.1.3. Competitive Pricing Strategies
3.2.2. Market Restraint Analysis
3.2.2.1. Data insecurity
3.2.2.2. Third-party performance
3.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET: SERVICES ESTIMATES & TREND ANALYSIS
4.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Segment Dashboard
4.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Movement Analysis
4.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By Services, 2018 - 2030
4.4. Bioanalytical Testing
4.4.1. Bioanalytical Testing Market, 2018 to 2030 (USD Million)
4.4.2. Clinical
4.4.2.1. Clinical Market, 2018 to 2030 (USD Million)
4.4.3. Non- Clinical
4.4.3.1. Non- Clinical Market, 2018 to 2030 (USD Million)
4.5. Method Development and Validation
4.5.1. Method Development and Validation Market, 2018 to 2030 (USD Million)
4.5.2. Extractable and Leachable
4.5.2.1. Extractable and Leachable Market, 2018 to 2030 (USD Million)
4.5.3. Impurity Method
4.5.3.1. Impurity Method Market, 2018 to 2030 (USD Million)
4.5.4. Technical Consulting
4.5.4.1. Technical Consulting Market, 2018 to 2030 (USD Million)
4.5.5. Other Method Validation Services
4.5.5.1. Other Method Validation Services Market, 2018 to 2030 (USD Million)
4.6. Stability Testing
4.6.1. Stability Testing Market, 2018 to 2030 (USD Million)
4.6.2. Drug Substance
4.6.2.1. Drug Substance Market, 2018 to 2030 (USD Million)
4.6.3. Stability Indicating Method Validation
4.6.3.1. Stability Indicating Method Validation Market, 2018 to 2030 (USD Million)
4.6.4. Accelerated Stability Testing
4.6.4.1. Accelerated Stability Testing Market, 2018 to 2030 (USD Million)
4.6.5. Photostability Testing
4.6.5.1. Photostability Testing Market, 2018 to 2030 (USD Million)
4.6.6. Other Stability Testing Methods
4.6.6.1. Other Stability Testing Methods Market, 2018 to 2030 (USD Million)
4.7. Other Testing Services
4.7.1. Other Testing Services Market, 2018 to 2030 (USD Million)
CHAPTER 5. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Segment Dashboard
5.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Movement Analysis
5.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market, 2018 to 2030 (USD Million)
5.5. Biopharmaceutical Companies
5.5.1. Biopharmaceutical Companies Market, 2018 to 2030 (USD Million)
5.6. Contract Research Organizations
5.6.1. Contract Research Organizations Market, 2018 to 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Market Participant Categorization
6.1.1. Innovators
6.1.2. Market Leaders
6.1.3. Emerging Players
6.1.4. Company Market Share Analysis, 2024
6.2. Company Profiles
6.2.1. West Pharmaceutical Services, Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Service Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. SGS SA
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Service Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Eurofins Scientific
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Service Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Pace Analytical Services Llc
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Service Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Intertek Group PLC
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Service Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Pharmaceutical Product Development, LLC.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Service Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Wuxi Apptec, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Service Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Boston Analytical
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Service Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. Charles River Laboratories International, Inc.
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Service Benchmarking
6.2.9.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Services
1.2.2. End Use
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing innovation in testing services
3.2.1.2. Growing regulation, safety & quality requirements
3.2.1.3. Competitive Pricing Strategies
3.2.2. Market Restraint Analysis
3.2.2.1. Data insecurity
3.2.2.2. Third-party performance
3.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET: SERVICES ESTIMATES & TREND ANALYSIS
4.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Segment Dashboard
4.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Movement Analysis
4.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By Services, 2018 - 2030
4.4. Bioanalytical Testing
4.4.1. Bioanalytical Testing Market, 2018 to 2030 (USD Million)
4.4.2. Clinical
4.4.2.1. Clinical Market, 2018 to 2030 (USD Million)
4.4.3. Non- Clinical
4.4.3.1. Non- Clinical Market, 2018 to 2030 (USD Million)
4.5. Method Development and Validation
4.5.1. Method Development and Validation Market, 2018 to 2030 (USD Million)
4.5.2. Extractable and Leachable
4.5.2.1. Extractable and Leachable Market, 2018 to 2030 (USD Million)
4.5.3. Impurity Method
4.5.3.1. Impurity Method Market, 2018 to 2030 (USD Million)
4.5.4. Technical Consulting
4.5.4.1. Technical Consulting Market, 2018 to 2030 (USD Million)
4.5.5. Other Method Validation Services
4.5.5.1. Other Method Validation Services Market, 2018 to 2030 (USD Million)
4.6. Stability Testing
4.6.1. Stability Testing Market, 2018 to 2030 (USD Million)
4.6.2. Drug Substance
4.6.2.1. Drug Substance Market, 2018 to 2030 (USD Million)
4.6.3. Stability Indicating Method Validation
4.6.3.1. Stability Indicating Method Validation Market, 2018 to 2030 (USD Million)
4.6.4. Accelerated Stability Testing
4.6.4.1. Accelerated Stability Testing Market, 2018 to 2030 (USD Million)
4.6.5. Photostability Testing
4.6.5.1. Photostability Testing Market, 2018 to 2030 (USD Million)
4.6.6. Other Stability Testing Methods
4.6.6.1. Other Stability Testing Methods Market, 2018 to 2030 (USD Million)
4.7. Other Testing Services
4.7.1. Other Testing Services Market, 2018 to 2030 (USD Million)
CHAPTER 5. U.S. PHARMACEUTICAL ANALYTICAL TESTING OUTSOURCING MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Segment Dashboard
5.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Movement Analysis
5.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market, 2018 to 2030 (USD Million)
5.5. Biopharmaceutical Companies
5.5.1. Biopharmaceutical Companies Market, 2018 to 2030 (USD Million)
5.6. Contract Research Organizations
5.6.1. Contract Research Organizations Market, 2018 to 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Market Participant Categorization
6.1.1. Innovators
6.1.2. Market Leaders
6.1.3. Emerging Players
6.1.4. Company Market Share Analysis, 2024
6.2. Company Profiles
6.2.1. West Pharmaceutical Services, Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Service Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. SGS SA
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Service Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Eurofins Scientific
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Service Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Pace Analytical Services Llc
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Service Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Intertek Group PLC
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Service Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Pharmaceutical Product Development, LLC.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Service Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Wuxi Apptec, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Service Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Boston Analytical
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Service Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. Charles River Laboratories International, Inc.
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Service Benchmarking
6.2.9.4. Strategic Initiatives
